US Bancorp’s Rein Therapeutics RNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.63K Hold
1,250
﹤0.01% 3849
2025
Q4
$1.45K Hold
1,250
﹤0.01% 3803
2025
Q3
$1.43K Hold
1,250
﹤0.01% 3791
2025
Q2
$1.75K Hold
1,250
﹤0.01% 3885
2025
Q1
$2.21K Hold
1,250
﹤0.01% 3858
2024
Q4
$2.88K Hold
1,250
﹤0.01% 3783
2024
Q3
$4.42K Hold
1,250
﹤0.01% 3608
2024
Q2
$3.46K Hold
1,250
﹤0.01% 3603
2024
Q1
$8.29K Hold
1,250
﹤0.01% 3399
2023
Q4
$3.81K Hold
1,250
﹤0.01% 3588
2023
Q3
$1.9K Hold
1,250
﹤0.01% 3664
2023
Q2
$2.24K Hold
1,250
﹤0.01% 3662
2023
Q1
$1.55K Hold
1,250
﹤0.01% 3814
2022
Q4
$2.96K Hold
1,250
﹤0.01% 3673
2022
Q3
$5K Hold
1,250
﹤0.01% 3630
2022
Q2
$7K Hold
1,250
﹤0.01% 3493
2022
Q1
$13K Hold
1,250
﹤0.01% 3296
2021
Q4
$14K Hold
1,250
﹤0.01% 3303
2021
Q3
$26K Hold
1,250
﹤0.01% 3002
2021
Q2
$31K Hold
1,250
﹤0.01% 2914
2021
Q1
$36K Hold
1,250
﹤0.01% 2752
2020
Q4
$26K Hold
1,250
﹤0.01% 2801
2020
Q3
$32K Hold
1,250
﹤0.01% 2599
2020
Q2
$30K Hold
1,250
﹤0.01% 2643
2020
Q1
$8K Hold
1,250
﹤0.01% 3116
2019
Q4
$14K Hold
1,250
﹤0.01% 3015
2019
Q3
$17K Hold
1,250
﹤0.01% 2909
2019
Q2
$18K Buy
+1,250
New +$32.8K ﹤0.01% 2928

Other funds holding RNTX

US Bancorp's RNTX Position: Q1 2026 in Review

US Bancorp held its Rein Therapeutics (RNTX) position steady in Q1 2026 at 1,250 shares worth $1.63K. The position accounts for ﹤0.01% of the portfolio, ranked #3849.

US Bancorp first reported a position in RNTX in Q2 2019 and has held it in 28 quarters since. The position peaked at $36K in Q1 2021. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • US Bancorp held 1,250 shares of Rein Therapeutics worth $1.63K as of Q1 2026.
  • US Bancorp left its Rein Therapeutics share count unchanged in Q1 2026.
  • Rein Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3849 holding.
  • US Bancorp first reported a position in Rein Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • US Bancorp's Rein Therapeutics position peaked at $36K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.